Systemic sclerosis is characterised by a vascular disorder and excessive deposition of collagen and other matrix proteins in the skin and internal organs.' Symptoms and signs of lung disease are rare when patients first present, yet up to 80% have abnormal lungs at necropsy. 23 The histological appearances are identical to those of cryptogenic fibrosing alveolitis. 4 The investigation of patients with systemic sclerosis offers an opportunity therefore to study fibrosing alveolitis from the earliest stages of its evolution.
Symptomless patients with collagen vascular disorders, including a few with systemic sclerosis, have evidence of subclinical alveolitis.' There are, however, currently no data to indicate whether this alveolitis is associated with other pathological processes, such as pulmonary vascular leakage of plasma proteins or altered lung collagen metabolism.
The aim of this study was to examine the lower respiratory tract of patients with systemic sclerosis for evidence of pulmonary vascular leakage, inflammatory cell infiltration, and enhanced lung collagen metabolism.
Methods

PATIENTS
We investigated 34 [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] years.
Lavage fluid was centrifuged at 300 g for five minutes, and the supernatant stored at -40°C. The cell pellet was resuspended and the total and differential cell count determined immediately.9 Blood was collected from all subjects at the time of bronchoscopy and serum stored at -40°C. Albumin concentrations were measured calorimetrically in 20 Jul aliquots of serum and 1 ml aliquots of unconcentrated lavage fluid, the Bromocresol Green binding reaction being used (Sigma Chemical Company, Poole, Dorset). 
Results
LAVAGE FLUID ALBUMIN AND CELLULARITY
The albumin concentrations in both groups of patients with systemic sclerosis were significantly greater than those from control subjects, when values were expressed both as absolute amounts and as lavage fluid: serum ratios (table 2) . The total number of cells recovered from each subject varied considerably and no differences between the groups were observed (table 2) . The differential cell counts show that patients with an abnormal computed tomogram had higher proportions of Lavage fluid cell counts in our study showed id not that patients with systemic sclerosis and on or evidence of fibrosing alveolitis as a group had f the higher proportions of neutrophils, eosinophils, and lymphocytes than control subjects, confir- The serum procollagen N peptide concentrations we found are similar to those previously reported for both normal volunteers25 and patients with systemic sclerosis. 26 Our results indicate that the measurement of serum procollagen N peptide does not distinguish patients with clinical evidence of pulmonary fibrosis from those without. By contrast, our results for bronchoalveolar lavage fluid suggest a progressive increase in type III collagen synthesis with the development of pulmonary fibrosis, though these data do not necessarily indicate that type III collagen is laid down as mature collagen fibrils in the lung interstitium. Nevertheless, our results complement those of previous morphometric27 and biochemicall29 studies, in which an increased lung collagen content was found in fibrosing alveolitis.
The lack of correlation between procollagen N peptide concentrations in lavage fluid and results of physiological tests of lung function requires explanation. Our data could mean that raised procollagen N peptide concentrations in lavage fluid, and by implication increased type III collagen synthesis by the lung, may occur very early in the pathogenesis of pulmonary fibrosis, at a stage undetectable by conventional techniques, including computed tomography of the thorax. It has been suggested that in areas of established pulmonary fibrosis type III collagen tends to be replaced by type I collagen27; in the patients with advanced lung disease therefore lavage fluid procollagen N peptide might be expected to return to more modest levels.
Our observations suggest increased pulmonary vascular permeability in patients with systemic sclerosis and concentrations of procollagen N peptide in lavage fluid might reflect leakage of these antigens from the circulation. There is evidence to refute this proposal, however. There was no correlation between albumin and procollagen N peptide in lavage fluid and an appreciable number of patients had a concentration of the peptide in their lavage fluid which, in relation to the albumin concentration, still greatly exceeded the level in their serum. This suggests enhanced type III collagen production by the lungs.
Increased concentrations of procollagen N peptide in bronchoalveolar lavage fluid from patients with other interstitial lung diseases have been reported,223>32 but this is the first study of pulmonary disease in systemic sclerosis. All previous studies were based on a radioimmunoassay using whole IgG antiprocollagen N peptide." Although this assay is very sensitive, it preferentially measures the Col 1-3 antigen. Type III procollagen peptides in lavage fluid may occur in several different antigenic forms34 and the assay using whole antibody may be less appropriate for use on lavage fluid, though it is the Col 1-3 peptide that probably reflects collagen synthesis most accurately. Despite differences in the assays, data from the present and previous studies suggest that procollagen peptides in lavage fluid reflect altered type III collagen metabolism of the lung interstitium in vivo.
This study suggests that increased pulmonary vascular leakage and neutrophil alveolitis may be early features of interstitial lung disease in systemic sclerosis and that these abnormalities are frequently associated with evidence of enhanced lung type III collagen synthesis. Possibly these inflammatory changes could resolve in some patients without the development of lung fibrosis. These findings are likely to be relevant to the early clinical diagnosis of pulmonary fibrosis and to investigators interested in understanding its pathogenesis.
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